Core Insights - Editas Medicine is focusing on becoming a premier in vivo gene editing company, particularly since the appointment of CEO Gilmore three years ago [4]. Group 1: Company Strategy - The company has generated exciting data in the field of in vivo gene editing, which they are eager to advance [4]. - Editas is refining its focus on in vivo development to address unmet needs in genetic disorders such as thalassemia and sickle cell disease [3][4]. Group 2: Market Landscape - There is significant potential in the treatment landscape for thalassemia and sickle cell, with current approved options having weaknesses that in vivo solutions could address [5].

Core Insights - Editas Medicine has achieved therapeutically relevant gene editing levels in the HBG1/2 promoter and a favorable biodistribution profile in non-human primates, supporting the development of treatments for sickle cell disease and beta thalassemia [1][2]. Group 1: Study Findings - New data from preclinical studies in non-human primates will be presented at the European Hematology Association (EHA) 2025 Congress, highlighting the potential of Editas' proprietary HSC-tLNP for gene editing [1][2]. - The study demonstrated editing levels exceeding the predicted threshold of ≥25% required for therapeutic benefit with a single dose [5]. Group 2: Presentation Details - The poster presentation titled "Targeted Lipid Nanoparticle Delivery Enables In Vivo HBG1/2 Genome Editing In Non-Human Primates" is scheduled for June 14, 2025, at the Allianz MiCo in Milan, Italy [4]. - The presentation will be accessible on the Editas Medicine website during the conference [3]. Group 3: Company Overview - Editas Medicine focuses on translating CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into in vivo medicines for serious diseases [4]. - The company is the exclusive licensee of Broad Institute's Cas12a and Cas9 patent estates for human medicines [4].

Core Insights - Editas Medicine has demonstrated therapeutically relevant levels of HBG1/2 promoter editing in hematopoietic stem cells using a proprietary targeted lipid nanoparticle (tLNP) approach, supporting its potential as a novel treatment for sickle cell disease and beta thalassemia [1][2][3] Group 1: Research Findings - The proprietary tLNP formulation achieved up to 47% HBG1/2 editing levels in non-human primates (NHPs) and 48% in humanized mice, exceeding the ≥25% threshold required for therapeutic benefit [2] - Preliminary biodistribution data indicates significant liver de-targeting with Editas' tLNP compared to standard lipid nanoparticles [2] Group 2: Clinical Development - The in vivo HSC program targets HBG1/2 promoters to mimic hereditary persistence of fetal hemoglobin (HPFH) and utilizes AsCas12a for high efficiency and minimized off-target editing [3] - The investigational medicine reni-cel has shown robust increases in fetal hemoglobin (HbF) and total hemoglobin (Hb) in clinical trials [3] Group 3: Presentation Details - Editas Medicine presented these findings at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) on May 14, 2025, with a session focused on translational applications of gene editing [4] - Additional poster presentations included topics on improved LNP targeting ligands and chemically modified AsCas12a guide RNAs [5][6] Group 4: Company Overview - Editas Medicine is focused on translating CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into in vivo medicines for serious diseases [7] - The company aims to discover, develop, manufacture, and commercialize transformative gene editing medicines, holding exclusive licenses for key CRISPR patents [7]

Summary of Editas' Conference Call Company Overview - **Company**: Editas Medicine - **Industry**: Biotechnology, specifically focusing on gene editing and therapy Key Points and Arguments Focus on In Vivo Development - Editas aims to be a premier in vivo gene editing company, refining its focus since the CEO's arrival three years ago [5] - The company has generated promising data in in vivo gene editing, particularly for sickle cell disease, which is seen as a significant opportunity [6][7] Market Potential and Treatment Efficacy - In vivo gene editing is expected to expand the market and reduce patient burden compared to ex vivo therapies [6] - The company believes that the efficacy bar for in vivo treatments is on par or better than ex vivo options, allowing for a larger patient population [9] Preclinical Data and Optimization - Editas is applying learnings from its ex vivo program to optimize its in vivo gene editing approach, focusing on delivery mechanisms [10][11] - Proprietary TLNP technology is showing great potential in preclinical settings [11] Business Development and Pipeline Expansion - The company is exploring additional investments and partnerships to expand its pipeline, particularly in in vivo applications [13][17] - Editas is focused on being best-in-class in vivo gene therapy, with a strategic approach to target functional proteins [15][16] Financial Position and Capital Efficiency - Editas has a cash runway extending into Q2 2027, providing breathing room to advance its in vivo programs [19][21] - The company is being capital efficient, particularly in managing wind-down costs from previous programs [26] Licensing Agreements and Intellectual Property - Current licensing agreements remain unaffected by recent legal decisions, and Editas is open to new licensing opportunities [28][29] Upcoming Data and Milestones - Editas presented data at ASGCT, showing over 80% reduction in a disease biomarker in its liver program [32] - The company plans to declare two drug candidates by mid-2025 and file an IND for one candidate in 2026, with potential human proof of mechanism expected by late 2026 to early 2027 [36] Conclusion - Editas is focused on advancing its in vivo gene editing capabilities while maintaining a strong financial position and exploring new partnerships to enhance its pipeline [41]

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Editas Medicine (EDIT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Editas Medicine is one of 1001 individual stocks in the Medical sector. Collectiv ...

Editas Medicine (EDIT) reported an adjusted loss of 43 cents per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 51 cents. The adjusted figure excluded the effect of restructuring and impairment charges in the reported quarter. The company had incurred a loss of 76 cents per share in the year-ago quarter.Collaboration and other research and development (R&D) revenues, which comprise the company’s top line, were $4.7 million in the reported quarter, up significantl ...

In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today shared in vivo proof of concept data supporting the development of a potentially first-in-class treatment for an undisclosed liver target in a poster presentation at the 28th Annual Meeting of the American Society of Gene and Cell Th ...

Core Insights - Editas Medicine reported a quarterly loss of $0.43 per share, better than the Zacks Consensus Estimate of a loss of $0.51, and an improvement from a loss of $0.76 per share a year ago, resulting in an earnings surprise of 15.69% [1] - The company generated revenues of $4.66 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 385.21%, compared to $1.14 million in the same quarter last year [2] - Editas shares have increased by approximately 14.2% since the beginning of the year, contrasting with a -3.8% decline in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.40 on revenues of $0.98 million, and for the current fiscal year, it is -$1.53 on revenues of $6.74 million [7] - The estimate revisions trend for Editas is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Editas belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________ OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ________ Commission File Number 001-37687 _______________________________ EDITAS MEDICINE, INC. (Exact name of registrant as specified in its charter) _______________________________ FORM 10-Q _______________________________ (Mark One) ☐ QUARTERLY R ...

"We achieved notable progress in the first quarter, advancing our mission and strategy to become a leader in in vivo gene editing. This momentum was fueled by recent scientific breakthroughs that bolster our confidence in the near-term potential of CRISPR-based in vivo gene editing therapies," said Gilmore O'Neill, M.B., M.M.Sc., President and Chief Executive Officer of Editas Medicine. "I'm proud of the strides made by the Editas team in driving our in vivo gene editing programs, which we believe could unl ...